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reproduction in any medium, provided the original work iDrug resistance continues to be a major barrier to the delivery of curative therapies
in cancer. Historically, drug resistance has been associated with over-expression ofg transporters, changes in drug kinetics or amplification of drug targets. How-
er, the emergence of resistance in patients treated with new-targeted therapies
s provided new insight into the complexities underlying cancer drug resistance.
cent data now implicate intratumoural heterogeneity as a major driver of drug
istance. Single cell sequencing studies that identified multiple genetically distinct
riants within human tumours clearly demonstrate the heterogeneous nature of
man tumours. The major contributors to intratumoural heterogeneity are (i)
netic variation, (ii) stochastic processes, (iii) the microenvironment and (iv) cell
d tissue plasticity. Each of these factors impacts on drug sensitivity. To deliver
rative therapies to patients, modification of current therapeutic strategies to
lude methods that estimate intratumoural heterogeneity and plasticity will be
ential.Cancer drug resistance
contributes to treatment
failure
Cure or control of disseminated disease
remains the greatest challenge facing
cancer clinicians/scientists, and the
greatest cause of patient mortality.
Advances in surgery and radiation
oncology provide cures for many forms
of malignancy. However, these
advances are unlikely to produce
substantial improvements in cures
for patients with metastatic disease.The control of malignancies beyond the primary site of the
tumour, requires systemic therapeutic strategies. Systemicnsland, Diamantine
Australia
ospital, University of
ueensland, Australia
and, Woolloongabba,
t. Vincent’s Hospital,
re Hospital, Sydney,
ey, New South Wales,
1732405946;
Ltd on behalf of EMBO. Thi
ercial License, which perm
s properly cited.chemotherapy-based treatments for cancer emerged in the
1940s to 1960s amid considerable resistance from the clinical
community (DeVita & Chu, 2008). Single drug treatments for
cancer were widely practiced until the 1960’s when DeVita and
coworkers championed the concept of combination chemother-
apy. The rationale for their approach was to combine agents
with different modes of action, thereby increasing the likelihood
of synergistic anti-cancer effects (Devita & Schein, 1973). By the
mid-1970’s, combination chemotherapy had increased the
complete remission rate for Hodgkin’s lymphoma from 20 to
80% and for lymphosarcoma from 15% to over 50% (Devita &
Schein, 1973). With few exceptions, combination chemotherapy
is now standard practice when treating both primary and
secondary tumours. Despite these advances, a significant
fraction of advanced human malignancies remain refractory
to curative attempts with conventional chemotherapeutics
mainly due to inherent or acquired drug resistance.s is an open access article under
its use, distribution and
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676In the last decade, there has been a large effort to identify
specific mutations within tumours that could be exploited as
therapeutic targets. We now have clinical experience with several
new classes of ‘targeted’ and ‘non-targeted’ therapies such as
anti-angiogenic drugs, anti-stromal drugs, immune modulators,
epigenetic modifiers and inhibitors of various growth factors and
their signalling pathways. Patient response to these drugs has
varied from profound curative responses (Kwak et al, 2010; Rosti
et al, 2012) through to transient (Flaherty et al, 2010; Sampson
et al, 2010) or poor responses (Garraway & Janne, 2012). Despite
the success of targeted and non-targeted approaches to treating
cancers, the emergence of resistant disease continues to be a
significant cause of patient mortality.
Tumour Drug resistance can be inherent or acquired and is
mediated by multiple biochemical processes operating indivi-
dually or in combination (Fodale et al, 2011). Known factors that
lead to drug resistance include (i) induction of drug transporters,
(ii) activation of DNA repair, (iii) changes in drug metabolism,
(iv) gene amplification or mutation of target proteins and
(v) changes in survival/apoptotic pathways. The ATP-binding
cassette (ABC) family of drug transporters comprises 48 genes
that code for transmembrane pumps that are selectively
involved in the efflux of small molecule drugs and toxins
(Fukuda & Schuetz, 2012). Some of these transporters have been
shown to play a specific role in pumping cytotoxic drugs out of
the cell preventing the accumulation of cytotoxic concentrations
within the cell and hence invoking drug-resistance (Fukuda &
Schuetz, 2012). DNA repair pathways comprise a complex
network of proteins able to sense DNA damage (e.g.: ATM, ATR,
Chk1/2, BRCA1 or p53) through to the machinery required to
repair the damage. Drug metabolizing enzymes such as the
cytochrome P450 family of enzymes or the glucuronyl
transferases are responsible for the biotransformation of many
anti-cancer drugs and their activity contributes to the modula-
tion of intracellular drug levels. This contributes to the
sensitivity of cancer cells to cytotoxic drugs. In addition to
these regulators of drug sensitivity, gene amplification of
receptors, such as EGF receptor, targeted by tyrosine kinaseGlossary
Clonal variant
Genetically/epigenetically distinct variants of tumour cells within an
individual tumour that had a common cell of origin.
Combination chemotherapy
The use of a defined cocktail of chemotherapeutics that individually have
different modes of action but when delivered in combination have greater
anti-cancer effects.
Conventional chemotherapeutic
Therapeutic agents that are designed to induce a cytotoxic, cytostatic or
immune response regardless of the underlying defects that contribute to
cancer development.
Intratumoural heterogeneity
Refers to the variation in genome, epigenome, proteome and cell and tissue
behaviour that is found within an individual tumour and its stromal
constituents.
 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.inhibitors can often compromise the efficacy of therapies.
Finally, the relative activities of pro-apoptotic and anti-apoptotic
(survival) pathways contribute to the sensitivity of a cancer cell
to a cytotoxic stimulus (see Chonghaile & Letai, 2008; Engelman,
2009). Combined, these broad, overlapping, mechanisms are
the main biochemical determinants of cancer cell sensitivity to
cytotoxic drugs (excluding anatomical or diffusional considera-
tions). Therapeutic strategies to modify drug transporters (see
Haar et al, 2012), drug metabolism and survival pathways
(see Chonghaile & Letai, 2008; Engelman, 2009) have all been
developed and trialed in patients. However, further resistance
frequently occurs followed by disease relapse and progression.
Thus, knowing the main biochemical contributors to resistance
has not led to the development of tests that are predictive of
tumour behaviour, nor has it led to substantive improvements in
patient outcomes.
The emergence of resistance to the diverse range of drugs
available for cancer treatment is indicative of the dynamic
nature of tumour tissue. Recent evidence emerging from studies
in which the tumour environment was interrogated suggests
that a more fundamental driver of resistance is intratumoural
heterogeneity (Ding et al, 2012; Navin et al, 2011; Ruiz et al,
2011; Xu et al, 2012). These studies highlight the likelihood that
tumours comprise cancer cells that vary in their sensitivity to
chemotherapeutics due to genotypic or phenotypic variation.
This is an important finding because the basis of resistance has
significant implications for the management of cancer patients.
Heterogeneity, in this context, refers to variation in tissue
response, tissue composition, tissue physiology, tissue pheno-
type and tissue genotype. For example, genomic heterogeneity
may arise through heritable genetic and epigenetic mechanisms
and is exemplified by the presence of discrete clonal variants
within a tumour (Navin et al, 2011), the potential presence of
tumour initiating subpopulations of cells (Bonnet & Dick, 1997;
Lapidot et al, 1994) or cells with a characteristic ‘mutator’
phenotype (see Kolodner et al, 2011). Phenotypic heterogeneity
may result from genomic heterogeneity but also can result from
stroma/tumour cell interactions, tumour cell/tumour cellPlasticity
The ability of a cell to reversibly and flexibly change lineage or to
modify cell behaviour through alteration in differentiation programming.
Stochastic process
A process that is determined by random events.
Systems biology
The field of biology that attempts to explain cell, tissue and organism
behaviour based on a knowledge of all the interactions that occur between
the biological networks within the system.
Targeted therapies
Therapeutic agents that modulate the activity of specific molecules which
a cancer is known to be dependent upon.
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Figure 1. Scheme depicting the basis for heterogeneity in drug responses
within a tumour. The different clonal variants present within tumours are
represented by the different coloured cells. Heterogeneity, within a clonal
variant, due to stromal interaction is marked by * whilst heterogeneity
attributable to plasticity/EMT is marked by ^^. Finally, heterogeneity in an
identical clone due to stochastic variation is marked.interactions or simply as a result of the stochastic nature of
biological processes (Fig 1). All of these contributors to
intratumoural heterogeneity are likely to be operative simulta-
neously and highlight why resistance is likely to be dynamic.Biological determinants of intratumoural
heterogeneity
Understanding the biological and genetic basis for how cells
acquire heterogeneity has important implications for how we
manage patients. The acquisition of intratumoural heterogene-
ity is frequently modelled on evolutionary principles (Gerlinger
et al, 2012; Polyak, 2007). In these models, a tumour is assumed
to derive from a single founder cell that has acquired a mutation
in a critical gene. This mutation is passed on to progeny that are
subject to further lesional events, resulting in the production of
progeny that continue to acquire genetic/epigenetic mutations
leading to a fully transformed malignancy comprising many
clonal variants (Ding et al, 2012; Gerlinger et al, 2012; Polyak,
2007). Two models of tumour evolution have been proposed;
the cancer stem cell model and the clonal evolution model
(Polyak, 2007; Shackleton et al, 2009). Both accommodate the
generation and expansion of genotypic and phenotypic variants
within tumours. The major point of difference between the
models is whether tumour initiating and self-renewal activity is
restricted to a fixed subpopulation of cells or is shared by all the
variant clones within the tumour.www.embomolmed.org EMBO Mol Med 4, 675–684 The cancer stem cell model proposes that there is a fixed, rare,
subpopulation of cancer cells that possess stem-like activity
with respect to their self-renewal capacity and ability to initiate a
tumour in xenotransplant models (Bonnet & Dick, 1997;
Lapidot et al, 1994; Shackleton et al, 2009). This model is
strongly supported by data from human leukaemias such as
acute myeloid leukaemia (AML) (Bonnet & Dick, 1997; Lapidot
et al, 1994). Cells enriched from patients with AML could be
divided into populations that differed in the expression of
specific surface molecules. The bulk of AML cells was
CD32CD38 and, when injected into immunocompromised
mice, could not initiate a tumour. By contrast, the rare
CD32þCD38 fraction of cells could initiate tumours with high
efficiency (Bonnet & Dick, 1997; Lapidot et al, 1994). There have
now been a number of studies in other tumour types, including
pancreatic cancer, breast cancer, head and neck cancer and
medulloblastoma, which have also reported the presence of rare
stem-like cells within tumours (Al-Hajj et al, 2003; Bao et al,
2006; Li et al, 2007; Prince et al, 2007). In contrast, the clonal
evolution model allows most, if not all, cells to retain a capacity
for self-renewal and tumour initiating activity. Thus, from a
therapeutic point of view, the cancer stem cell model would
require ablation of the cancer stem cell population to invoke a
cure whereas the clonal evolution model would require the
ablation of all clonal variants to invoke a cure. However, both
models allow for the generation of genotypically discrete clonal
variants that could differ with respect to chemotherapeutic
sensitivity. Recent reports have indicated that tumour cell
subpopulations can trans-differentiate into one another indicat-
ing that the rigid requirement of the cancer stem cell model, that
tumour initiating activity is restricted to a fixed population of
tumour cells, may be questioned (Chaffer et al, 2011; Gupta et al,
2011; Roesch et al, 2010). Whilst, these studies have only been
reported for breast cancer and melanoma, they do provide an
important conceptual framework to unify the two models.Evidence implicating intratumoural heterogeneity
as a driver of chemotherapy resistance in cancer
patients
Intratumoural heterogeneity is evident in human cancers and
most likely contributes to differing chemotherapeutic responses.
Hence, to improve cure rates, an understanding of the
contribution by intratumoural heterogeneity to drug resistance
is essential. The contributors to intratumoural heterogeneity are
genetic variation, stochastic processes, microenvironment and
cell and tissue plasticity (Fig 1). The evidence for the role of each
of these is discussed below.
Genetic variation and heterogeneous intratumoural
drug responses
The introduction of many new targeted therapies to clinical
practice provides support for the role of intratumoural hetero-
geneity in the loss of drug sensitivity. For example, a number of
studies have recently reported the use of comparative genomic
hybridization analysis and next generation sequencing to analyse2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 677
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Figure 2. Model depicting the selective resistance of specific clonal
variants in response to a chemotherapeutic. Clonal variants, of varying
chemotherapeutic sensitivity are represented by different colours.
678individual tumour cells isolated from primary breast cancers
(Navin et al, 2011), pancreatic adenocarcinomas (Ruiz et al,
2011), acute myeloid leukaemia (Ding et al, 2012) and renal cell
carcinoma (Gerlinger et al, 2012; Xu et al, 2012). There is now
definitive evidence showing that primary human tumours
contain genetically distinct subpopulations of tumour cells. In
primary breast cancers, glioblastomas, melanomas and renal cell
carcinomas, clonal variants not only exist within tumours but are
also confined to different sub-anatomic sites within the tumours
(Gerlinger et al, 2012; Navin et al, 2011; Snuderl et al, 2011;
Takata et al, 2000). Moreover, exome sequencing of single cells
isolated from a renal cell carcinoma showed that only 30% of the
genetic lesions within a tumour are common to all the cancer cells
(Gerlinger et al, 2012; Xu et al, 2012). Finally, several
independent studies have demonstrated that multiple clonal
variants exist within established head and neck cancer cell lines
(Cameron et al, 2010; Erlich et al, 2012; Poth et al, 2010).
Significantly, these variants differed with respect to their
transcriptomic profile, their sensitivity to chemotherapy, their
ability to initiate tumours, and their ability to interact with one
another to initiate tumours (Cameron et al, 2010; Erlich et al,
2012; Poth et al, 2010). Combined, these studies unequivocally
show that genetically distinct variants of tumour cells exist within
individual tumours in multiple tumour types.
There is increasing evidence demonstrating a role for
intratumoural heterogeneity in drug resistance. Many patients
have an immediate response to conventional cytotoxic thera-
pies, which can be followed by recurrence and resistance to
rechallenge with the same chemotherapeutic agents (DeVita &
Chu, 2008; Garraway & Janne, 2012). In some instances, a
relapsed tumour may be sensitive to a different chemotherapy
protocol and thus patients may undergo multiple cycles of
differing chemotherapeutic cocktails in pursuit of a sustained
response (DeVita & Chu, 2008; Garraway & Janne, 2012).
Similar clinical scenarios have been observed with the newer
targeted therapies. For example, the first generation BCR/ABL
kinase inhibitor, imatinib, or the V600E mutant-specific BRAF
inhibitor, Vemurafenib produce profound initial responses in
patients followed in many instances by the development of
resistance (Flaherty et al, 2010; Rosti et al, 2012; Villanueva
et al, 2010). In chronic myleogenous leukaemia, imatinib
resistance is frequently associated with tumour cells that no
longer harbour imatinib-sensitive mutations in the BCR-ABL
kinase (Garraway & Janne, 2012; Michor et al, 2005). Switching
patients to second-generation drugs with broader specificity,
such as dasatinib can overcome this resistance (Rosti et al,
2012). In the instance of BRAF V600E mutant-specific therapies,
resistance arises in a sub-population of cells in which IGF1
receptor signalling has been deregulated (Villanueva et al,
2010). Similarly, the recent trial of a vaccine against an EGF
receptor mutation in glioblastoma demonstrated a similar
transient response (Sampson et al, 2010). These trials clearly
show the clinical effectiveness of targeted therapies. However,
they also show that a paradoxical weakness of targeted therapies
may be the highly selective nature of their action. Thus, tumours
act as a repository of genetically variant transformed cells that
differ in their sensitivity to targeted therapies (Fig 2). 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.Emergence of drug resistance in patients receiving targeted or
non-targeted therapy is consistent with the presence of pre-
existing variants of tumour cells with varying drug sensitivities.
This is supported by molecular studies showing the presence of
sequence-verified tumour cell variants within individual human
tumours (Navin et al, 2011; Ruiz et al, 2011). Whilst
intratumoural genetic heterogeneity clearly has a capacity to
drive resistance it is ironic to note that drug treatment may
contribute to intratumoural genetic heterogeneity. A recent
study sequenced tumour cells from acute myeloid leukaemia
(AML) patients prior to and following treatment and relapse
(Ding et al, 2012). Relapse was accompanied by the emergence
of drug resistant clones (Ding et al, 2012). Moreover, in one
patient alone they found 330 tumour-specific mutations, 78
relapse-specific mutations and only 5 mutations that were
shared between the primary and relapsed tumours (Ding et al,
2012). In total, eight patients were sequenced and in all
instances they found that chemotherapy altered the mutational
and variant composition of the tumour resulting in genetically
distinct tumour cell variants in treated patients (Ding et al,
2012). These data indicate that the mutagenic properties of some
of the therapies currently in use could contribute to hetero-
geneity and hence could contribute to resistance.
Stochastic processes contribute to heterogeneous
intratumoural drug responses
The natural variation that occurs within any cell population is
often overlooked as a source of variation in chemotherapy. A
series of studies by Sorger and colleagues (Albeck et al, 2008;
Spencer et al, 2009) showed the extent of variation that can
occur within a genetically identical population of tumour cells in
response to a cytotoxic stimulus. They demonstrated that the
cytotoxic ligand TRAIL displayed considerable variability with
respect to the time and extent of cell death. Using cells stably
expressing proteins in the extrinsic apoptosis pathways, they
showed that the time to apoptosis, within any culture of
genetically identical cancer cells, varied and could be described
by a normal distribution. Those cells at extreme ends of the
distribution spectrum responded very differently to the same
dose of TRAIL (Spencer et al, 2009). This is not an isolated
observation. Gascoigne & Taylor (2008) reported a similar
finding by measuring the response to antimitotic chemother-EMBO Mol Med 4, 675–684 www.embomolmed.org
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Figure 3. Model depicting the impact of stromal interactions on the
sensitivity of identical clonal variants to chemotherapeutics. Identical
clonal variants are shown. Those cells that interact with the stroma are
marked by a star.apeutics in a number of cancer cell-lines (Gascoigne & Taylor,
2008). Combined, these studies indicate that genetically
identical cells under identical physical conditions differ in their
response to a given chemotherapeutic to an extent that may
impact on clinical response.
Microenvironmental factors contribute to heterogeneous
intratumoural drug responses
There is evidence that the tumour stroma actively contributes to
heterogeneous tumour behaviour and, in particular, chemo-
sensitivity. Stromal components can constitute greater than
50% of tumour mass. Tumour stroma comprises cellular and
non-cellular components such as fibroblasts, immunocytes and
structural proteins/fibres through to cells and tissue associated
with more complex structures such as blood vessels, muscles,
bone marrow or nerves. Stromal elements directly control
tumour cell behaviour and chemotherapeutic responses. For
example, Muranen et al (2012) showed that treatment of breast
and ovarian cancer cell lines with PI3K/mTOR inhibitors led to a
rapid cytotoxic response. However, they also observed that a
small population of cells consistently survived in 3D tissue
culture systems. The surviving cancer cells were characterized
by their close proximity and interaction with the matrigel in
which the cultures were grown (Muranen et al, 2012). Stromal
elements and stromal substitutes such as matrigel are known to
engage cellular receptors such as integrins. In this instance,
Muranen et al (2012) showed that PI3K/mTOR inhibitors
induced IGF1 receptor and EGF receptor, on those cells which
contacted the stroma. This led to the activation of antiapoptotic
pathways (e.g.: BCl2) resulting in drug resistance (Muranen
et al, 2012). Significantly, treatment of mice with EGF receptor
or IGF1 receptor inhibitors resulted in improved drug responses
to the PI3K/mTOR inhibitors in animal models of breast and
ovarian cancer (Muranen et al, 2012). Two important concepts
arise from this. Firstly, drug resistance may be attributable to a
subpopulation of tumour cells that, through their contact with
the basement membrane, have acquired drug resistance (Fig 3).
Secondly, these data show that chemoresistance can be
manipulated pharmacologically. Similarly, non-small cell lung
carcinoma (NSCLC) and breast cancers are associated with
significant stromal infiltration. In particular, expression of
proteins such as the integrins and their basement membrane
ligands, laminins, are overexpressed and disrupted in their
expression pattern (Desgrosellier & Cheresh, 2010). Laminin/
integrin ligation is known to activate intracellular pathways
such as NFkB, MAPK/ERK, PTEN/PI3K/Akt, resulting in
suppression of the cytotoxic response of breast, oral or NSCLC
cells to anoikis (Weaver et al, 2002), etoposide (Sethi et al,
1999; Weaver et al, 2002), doxorubicin (Sethi et al, 1999) or
cisplatin (Sansing et al, 2011). Thus, the interaction of tumour
cell surface receptors with adjacent stromal elements can
induce drug resistant behaviour in adjacent tumour cells
(Fig 3). The importance of stroma-mediated chemosensitivity
has been recognized and is the basis for the development, and
clinical trial, of agents such as the RGD-based inhibitors
of integrins (e.g.: cilengitide) in cancer patients (Vermorken
et al, 2011).www.embomolmed.org EMBO Mol Med 4, 675–684 Given the contribution of stromal elements to tumour cell
behaviour it was quickly realized that fibroblasts associated
with cancer tissue were different, phenotypically (Dicker et al,
2002; Elkabets et al, 2011; Place et al, 2011) and genomically
(Eng et al, 2009; Hu et al, 2005; Qiu et al, 2008) from fibroblasts
associated with normal tissues. The origin of this heterogeneity
is unclear. A recent study shows that cancers can be infiltrated
by stromal cells derived from the bone marrow (Elkabets et al,
2011). Thus, heterogeneity could arise in the resident tissue
fibroblasts or result from infiltration with fibroblasts of a
different origin. Despite the complexity of the origins of cancer
associated stromal cells it is clear that tumour behaviour is
dependent upon their presence and thus they offer an
opportunity for therapeutic intervention. For example, it has
been shown that cancer stroma could have a profound indirect
effect on the chemosensitivity of pancreatic cancer cells (Olive
et al, 2009; Provenzano et al, 2012). The insensitivity of
pancreatic cancers to gemcitabine was due, in part or wholly, to
the presence of a non-permeable stromal barrier that restricted
the ability of gemcitabine to reach the tumour cells. It was
shown that the use of Hedgehog antagonist, IPI-926, or the
hyaluronic acid disrupter, PEGPH20, collapsed the stroma
allowing gemcitabine to reach the tumour cells and induce
tumour cell death (Olive et al, 2009; Provenzano et al, 2012). In
this instance, the resistance to gemcitabine was directly
attributable to the anatomic heterogeneity within the tumour.
Tumour stroma contributes indirectly to chemotherapeutic
sensitivity by regulating tumour development/progression and
by exerting selection pressure on the evolving tumour. In this
way the stromal elements dictate the genetic/epigenetic/
phenotypic composition of the tumour and thereby modulate
chemotherapeutic sensitivity. Arguably the best example of
the pro-tumourigenic activity of stromal elements is seen by the
establishment and growth of tumour cells at metastatic sites. For2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 679
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Figure 4. Model depicting impact of tumour cell plasticity on
chemotherapeutic sensitivity. In this model a cell may give rise to individual
tumour cells of different lineage that differ in their sensitivity to a
chemotherapeutic agent.
680example, it has been shown that primary tumour cells are able to
contribute to the establishment of a premetastatic niche at
distant sites, which in turn, serves to attract and nurture the
growth of tumour cells that have left the site of the primary
malignancy (Kaplan et al, 2006). The best example of this would
be skeletal osteoclasts which are essential to the establishment
and growth of breast cancer cells at distant sites within the
skeleton (Guise et al, 2006; Mundy, 2002). The relationship
between the breast cancer cells and the osteoclasts is often
referred to as a ‘vicious cycle’ because primary breast cancer
cells release growth factors such as RANKL which stimulate the
growth and maturation of distant skeletal osteoclasts which
in turn resorb bone releasing matrix-associated growth factors
such as TGFb1 that attract and promote the growth of
breast cancer cells in the bone (Guise et al, 2006; Mundy,
2002). The establishment of skeletal metastases significantly
reduces patient lifespan and ablation of osteoclasts, using
bisphosphonates, significantly reduces patient morbidity and
increases lifespan such that it is now standard of care for
advanced metastatic breast cancer (Coleman, 2011). These data
provide a strong line of biological and clinical evidence showing
the importance of the tumour stroma to tumour cell growth and
the enormous clinical value of targeting this process. It is
noteworthy that recent studies have shown that metastatic foci
of medulloblastoma are genetically divergent from tumour cells
of the primary lesion (Wu et al, 2012) suggesting that the
establishment of metastatic foci may be selective for specific
variants of the primary tumour that have an inherent or
acquired capacity to migrate to, or take up residence, in the
premetastatic niche. Thus, the metastatic stroma and presence
of genetically distinct metastatic variants will contribute to
the differing chemosensitivities of metastatic lesions.
The innate immune system is an active participant in the
development of tumours. M1 macrophages, for example, are
tumour-suppressive and associated with good tumour responses
to therapy whilst M2 macrophages are pro-tumourigenic and
associated with tumour progression (Mosser & Edwards, 2008).
The relationship between macrophages and chemotherapeutic
response has now been demonstrated in breast cancer. Recent
data have shown that a high tumour associated macrophage to T
lymphocyte ratio in primary breast cancers was associated with a
poor prognosis (DeNardo et al, 2011). DeNardo et al (2011)
showed that high levels of colony stimulating factor-1 in breast
cancer led to the recruitment of tumour associated macrophages
which, in turn, suppressed the tumour-suppressive activity of T
lymphocytes and inhibited taxane-mediated cytotoxicity. Phar-
macological inhibition of tumour associated macrophage infil-
tration led to the sensitization of breast cancer cells to cytotoxic
drugs confirming their causal association with drug resistance
(DeNardo et al, 2011). Thus, there is clinical and experimental
evidence to show that the local tumour immune system
contributes to chemotherapeutic responses.
Contribution of tumour cell plasticity to heterogeneous
intratumoural drug responses
Tumour cells display considerable plasticity and this plasticity
extends to sensitivity to chemotherapeutics (Fig 4). In cancer, 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.plasticity refers to the ability of a cell to reversibly change
lineage or to modify cell behaviour beyond the normal
differentiation programme of that cell. Plasticity relating to
lineage transition is generally silenced in adult tissues with the
exception of some stem cell compartments (Tang, 2012). Thus,
the reinstatement of plasticity in cancer cells reflects a
pathological consequence of changes in the tumour cells or in
the adjacent tumour environment. From a therapeutic point of
view, plasticity is a confounding factor since cancer cells that
respond to a particular cytotoxic therapy may be insensitive to
chemotherapy if they have changed their phenotype. The best-
described example of cancer cell plasticity is the continuum
observed in the epithelial to mesenchymal transition (EMT) and
the reverse of this process, the mesenchymal to epithelial
transition (MET) (reviewed in Nieto, 2011). Studies of the EMT
have revealed a causal link between the EMT and the acquisition
of stem-like activities and chemoresistance. For example, the
mesenchymal phenotype in lung, pancreatic, and head and neck
cancer cells is associated with insensitivity to the clinically
approved EGFR-targeted agent erlotinib/Tarceva (Thomson
et al, 2005; Yauch et al, 2005). In particular, lung carcinoma cell
lines, which have undergone an EMT, exhibit reduced
sensitivity to erlotinib due to reduced dependence on the EGFR
pathway (Thomson et al, 2008; Yao et al, 2010). Moreover,
studies of drug sensitivity in various cancer cells, before or after
the EMT, show that following a mesenchymal transition cancer
cells are resistant to TRAIL (McConkey et al, 2009), radiation
(Bao et al, 2006; Nieto, 2011), paclitaxel (Cheng et al, 2007), and
cisplatin (Hsu et al, 2010; Latifi et al, 2011). Passage through the
EMT is regulated at a transcriptional level by a suite of
transcription factors such as Zeb1, Twist, Snail and Slug
(Arumugam et al, 2009; Nieto, 2011) that are responsible for the
phenotypic changes that accompany the EMT. In particular, the
loss of E-Cadherin expression is the classic marker of the EMT
and is controlled by Snail/Twist and Zeb1. Significantly, theseEMBO Mol Med 4, 675–684 www.embomolmed.org
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Nieto, 2011).
Plasticity is not restricted to EMT (Thompson & Haviv,
2011). Recent work has shown that different pathological
subtypes of breast cancer cells are able to give rise to one
another (Chaffer et al, 2011; Gupta et al, 2011). Specifically,
basal, ductal and stem-like cancer cell populations were isolated
from two different breast cancer cell-lines indicating that
established cell lines can stably retain intratumoural hetero-
geneity. Moreover, the authors showed that each of the different
cell subpopulations could give rise to all three lineages in
approximately the same proportions observed in the unsorted
population. It can be concluded that the different subpopula-
tions are not fixed in their phenotype. Of relevance to the present
review, it was reported that the stem-like cells were chemo-
resistant to paclitaxel and 5-fluorouracil and that expansion of
the other subtypes of cells following chemotherapeutic exposure
was due to the resistance of the stem cell fraction (Gupta et al,
2011). Interestingly, they found that all three populations of
cells could initiate tumour formation in vivo. Moreover, Roesch
et al (2010) showed that melanoma cells can be divided into
slow and fast replicating populations. The slow-cycling
population represented a small fraction of the melanoma cells
and was characterized by high levels of expression of the
demethylase enzyme Jarid1B (Roesch et al, 2010). Both
Jarid1Bþve and Jarid1Bve melanoma cells could initiate
tumours in vivo and could give rise to mixed populations of
Jarid1Bþve and Jarid1Bve melanoma cells (Roesch et al, 2010).
However, knockdown of Jarid1B reduced self-renewal suggest-
ing that Jarid1Bþve cells had stem-like qualities. Unfortunately,
the chemo-sensitivity of the Jarid1Bþve and Jarid1Bve popula-
tions was not examined (Roesch et al, 2010). Although these
studies are very recent and have not yet been validated in other
cancer types, they provide important insight into how
intratumoural heterogeneity evolves and how this may relates
to drug responses (Fig 4).Pending issues
Develop methods to estimate existing tumour heterogeneity
Develop techniques to quantitate the relative abundance of tumour
variants
Develop models that recapitulate the effects of genetic variants,
stroma, tissue plasticity and stochastic processes on chemother-
apeutic sensitivity
Develop therapeutic strategies to collapse tumour heterogeneity
Develop platforms to track changing heterogeneity during treatment
Develop systems biology-based platforms that predict tumour
complexity and drug sensitivity
Develop cost-effective platforms to individualise clinical manage-
ment of patients.Challenges posed by tumour heterogeneity
Whilst there has been some success with therapies targeting
pathways identified from profiling whole tumours (Flaherty
et al, 2010; Sampson et al, 2010), such strategies are yet to
deliver widespread improvements in cure or long-term survival.
A major limitation of global profiling of tumours is the inability
to identify clonal variant-specific lesions, potential tissue
interactions or plasticity within a tumour. Since these factors
are significant drivers of cancer drug resistance it is essential to
develop methods to estimate their potential contribution in any
tumour (see Pending issues).
Estimating intratumoural heterogeneity will be challenging.
Heterogeneity varies between and within tumour types as well
as within an individual tumour. Indeed, it has been reported that
within a tumour type there is <5% commonality of genetic
lesions (e.g.: Kan et al, 2010; Wood et al, 2007). This suggests
that profiling individual tumour types, using single cell
sequencing techniques, to estimate intratumoural heterogeneitywww.embomolmed.org EMBO Mol Med 4, 675–684 and molecular targets, may be needed for target-directed
personalized therapies in the future. Unfortunately, it remains
unclear how many genetically distinct variants may exist within
tumours at any time. Identifying driver mutation targets may
prove to be the easier part of this process since the ability to
sequence the genomes of individual tumour cells, is now
possible (Navin et al, 2011; Ruiz et al, 2011; Xu et al, 2012).
Whether it will have the sensitivity to quantitate the number of
different variants present within an individual tumour remains
unknown. However, the efficacy of existing targeted therapies
against their cognate target cells would suggest that approaches
that target multiple targets from multiple variants will invoke
good clinical responses.
An unresolved and more challenging complication relates to
the plasticity of tumour cells coupled with the instability that
drives genetic heterogeneity. Plasticity and genome instability
give rise to variant tumour behaviour and will remain major
barriers to the delivery of curative therapies. Furthermore, it will
be important to develop strategies that can modify tumour cell
plasticity. In this regard, such strategies would need to either
inhibit the transition to chemoresistant states or, encourage cells
to retain or acquire a chemo-sensitive phenotype. Because of the
complexity of tumours it will be important to develop experi-
mental systems that allow us to model processes that promote
intratumoural heterogeneity/plasticity and trial management
strategies in these models as a prelude to defining clinical
management protocols in patients. The complexity of tumours
would suggest that this will require integrated systems-biology-
based platforms in which we can input data relating to the
complexity and plasticity of an individual patients tumour and
output a clinical management strategy based on the identification
of multiple potential targets. In this instance, strategies that
combine target-directed therapies with non-targeted/ablative
therapies may help to simultaneously reduce tumour burden,
plasticity and complexity. Similarly, agents that modify immune
cell function or stroma may also provide powerful adjuncts to
targeted and conventional chemotherapeutics.
An additional issue relating to therapeutic approaches to
cancer treatment relates to whether all tumour cells need to be2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 681
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682ablated or whether a subclinical burden of disease is an
acceptable endpoint. Tumour dormancy studies show that
patients can harbour cancer cells without manifesting clinical
disease (Paez et al, 2012). However, it is likely that the threshold
for tolerance of cancer cells will be dependent upon the nature of
the transformations in the tumour cells (Leung & Brugge, 2012),
the plasticity of the tumour cells or the interactions of the
tumour cells with the adjacent environment. These are
important issues since a curative therapy would need to reduce
the tumour burden and heterogeneity to a level that is associated
with a low risk of recurrence.Acknowledgements
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